Similarly, our study demonstrated that GLP-1 RA use in insulin-treated patients was associated with a significantly lower risk of HF hospitalization than use of DPP-4 inhibitors or sulfonylureas. The gene discussed is DPP4; the disease is hydrops fetalis.